Pain and Pain Management

Living reference work entry

Abstract

Pain is one of the commonest symptoms encountered in palliative medicine. Good pain management involves ensuring pain is screened for, adequately assessed if present and appropriately managed. This includes targeted and systemic, nonpharmacological, and pharmacological approaches. This chapter seeks to give an evidence-based overview of approaches to screening for assessing and managing a patient’s pain.

References

  1. Abbey J, Piller N, De Bellis A, Esterman A, Parker D, Giles L, Lowcay B. The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs. 2004;10(1):6–13.PubMedGoogle Scholar
  2. Actavis. Product information fentanyl TD. 2012.Google Scholar
  3. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26(10):920–35.PubMedGoogle Scholar
  4. ANZCA, FPM. Opioid calculator app. 2017. Retrieved 22nd January, 2017.Google Scholar
  5. Archie P, Bruera E, Cohen L. Music-based interventions in palliative cancer care: a review of quantitative studies and neurobiological literature. Support Care Cancer. 2013;21(9):2609–24.PubMedPubMedCentralGoogle Scholar
  6. Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011;3Google Scholar
  7. Australian Adult Cancer Pain Management Guideline Working Party. Cancer pain management in adults. Cancer guidelines wiki. Sydney, Cancer Council Australia; 2016.Google Scholar
  8. Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173:536–40.PubMedGoogle Scholar
  9. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2015; 34(5):436–442.PubMedGoogle Scholar
  10. Bao Y, Kong X, Yang L, Liu R, Shi Z, Li W, Hua B, Hou W. Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Alternat Med. 2014;2014(9):170396.PubMedPubMedCentralGoogle Scholar
  11. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017;6:CD003351.PubMedGoogle Scholar
  12. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The faces pain scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. Pain. 1990;41(2):139–50.PubMedGoogle Scholar
  13. BioCSL. Versartis product information. 2015.Google Scholar
  14. Boyd C, Crawford C, Paat CF, Price A, Xenakis L, Zhang W. The impact of massage therapy on function in pain populations – a systematic review and meta-analysis of randomized controlled trials: part II, cancer pain populations. Pain Med. 2016;17(8):1553–68. pnw100PubMedPubMedCentralGoogle Scholar
  15. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835–42.PubMedGoogle Scholar
  16. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain. 1999;82(3):263–74.PubMedGoogle Scholar
  17. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European palliative care research collaborative guidelines project. Palliat Med. 2011;25(5):402–9.PubMedGoogle Scholar
  18. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68.PubMedGoogle Scholar
  19. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005;4:CD003345.Google Scholar
  20. Chambers WA. Nerve blocks in palliative care. Br J Anaesth. 2008;101(1):95–100.PubMedGoogle Scholar
  21. Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, Brundage M, DeAngelis C, Wong RKS. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(15):1463–72.PubMedGoogle Scholar
  22. Cleeland CS. The brief pain inventory user guide. M D Anderson Cancer Centre; 2009.Google Scholar
  23. Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;(5).Google Scholar
  24. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–82.PubMedPubMedCentralGoogle Scholar
  25. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387(10033):2093–105.PubMedGoogle Scholar
  26. Dale O, Moksnes K, Kaasa S. European palliative care research collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25(5):494–503.PubMedGoogle Scholar
  27. Davis MP, Temel JS, Balboni T, Glare P. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med. 2015;4(3):99–121.PubMedGoogle Scholar
  28. de Courcy JG. Interventional techniques for cancer pain management. Clin Oncol (R Coll Radiol). 2011;23(6):407–17.Google Scholar
  29. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1985–91.PubMedPubMedCentralGoogle Scholar
  30. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev. 2015a;(7).Google Scholar
  31. Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015b;(1).Google Scholar
  32. Derry S, Wiffen PJ, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017;7:CD012638.PubMedGoogle Scholar
  33. Dong ST, Butow PN, Costa DSJ, Lovell MR, Agar M. Symptom clusters in patients with advanced cancer: a systematic review of observational studies. J Pain Symptom Manag. 2014;48(3):411–50.Google Scholar
  34. Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD003726.PubMedGoogle Scholar
  35. Eccleston C, Hearn L, Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2015;10:CD011259.Google Scholar
  36. European Federation of Neurological Societies Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat P-F, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75.Google Scholar
  37. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105–11.PubMedGoogle Scholar
  38. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.PubMedPubMedCentralGoogle Scholar
  39. Fleming JAOC, B.D. Use of lidocaine patches for neuropathic pain in a comprehensive cancer Centre. Pain Res Manag. 2009;14(5):381–8.PubMedPubMedCentralGoogle Scholar
  40. France BD, Lewis RA, Sharma ML, Poolman M. Cordotomy in mesothelioma-related pain: a systematic review. BMJ Support Palliat Care. 2014;4(1):19–29.PubMedGoogle Scholar
  41. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(8).Google Scholar
  42. Garzon-Rodriguez C, Casals Merchan M, Calsina-Berna A, Lopez-Romboli E, Porta-Sales J. Lidocaine 5% patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer. 2013;21(11):3153–8.PubMedGoogle Scholar
  43. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(10).Google Scholar
  44. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.PubMedGoogle Scholar
  45. Hardy JR, Rees EAJ, Gwilliam B, Ling J, Broadley K, A’Hern R. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manag. 2001;21(3):204–9.Google Scholar
  46. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev. 2013;10:CD010270.Google Scholar
  47. Hans G, Robert D. Transdermal buprenorphine – a critical appraisal of its role in pain management. J Pain Res. 2009;2:117–34.PubMedPubMedCentralGoogle Scholar
  48. Haraldsplass Deaconess Hospital. Paracetamol for cancer pain trial. From https://clinicaltrials.gov/ct2/show/NCT01313247?term=paracetamol%2C+pain%2C+cancer&rank=2
  49. Haywood A, Good P, Khan S, Leupp A, Jenkins-Marsh S, Rickett K, Hardy JR. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev. 2015;4:CD010756.Google Scholar
  50. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;(2).Google Scholar
  51. Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014a;(5).Google Scholar
  52. Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014b;(9).Google Scholar
  53. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, Bayley M, Dowlatshahi D, Dukelow S, Garnhum M, Glasser E, Halabi M-L, Kang E, MacKay-Lyons M, Martino R, Rochette A, Rowe S, Salbach N, Semenko B, Stack B, Swinton L, Weber V, Mayer M, Verrilli S, DeVeber G, Andersen J, Barlow K, Cassidy C, Dilenge M-E, Fehlings D, Hung R, Iruthayarajah J, Lenz L, Majnemer A, Purtzki J, Rafay M, Sonnenberg LK, Townley A, Janzen S, Foley N, Teasell R. Canadian stroke best practice recommendations: stroke rehabilitation practice guidelines, update 2015. Int J Stroke. 2016;11(4):459–84.PubMedGoogle Scholar
  54. Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1–2):218–22.PubMedGoogle Scholar
  55. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and Metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.PubMedGoogle Scholar
  56. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci. 2001;2:83.PubMedGoogle Scholar
  57. Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2012;3:CD006276.Google Scholar
  58. International Association for the Study of Pain. Total cancer pain. 2009.Google Scholar
  59. International Association for the Study of Pain. IASP taxonomy.2017. Retrieved 19 Nov 2017, from https://www.iasp-pain.org/Taxonomy?navItemNumber=576
  60. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48(7):830–8.PubMedGoogle Scholar
  61. Johnson MI, Mulvey MR, Bagnall A-M. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. Cochrane Database Syst Rev. 2015a;8:CD007264.PubMedGoogle Scholar
  62. Johnson MI, Paley CA, Howe TE, Sluka KA. Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Syst Rev. 2015b;6:CD006142.Google Scholar
  63. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018;12(2):108–17.PubMedGoogle Scholar
  64. King S, Forbes K, Hanks G, Ferro C, Chambers E. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European palliative care research collaborative opioid guidelines project. Palliat Med. 2011;25(5):525–52.PubMedGoogle Scholar
  65. Kjellberg F, Tramèr MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001;18:346–57.PubMedGoogle Scholar
  66. Klepstad P, Kaasa S, Borchgrevink PC. Starting step III opioids for moderate to severe pain in cancer patients: dose titration: a systematic review. Palliat Med. 2011;25(5):424–30.PubMedGoogle Scholar
  67. Kane CM, Mulvey MR, Wright S, Craigs C, Wright JM, Bennett MI. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: systematic review and meta-analysis. Palliat Med. 2017;32(1):276–86.PubMedGoogle Scholar
  68. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13(3):219–30.PubMedGoogle Scholar
  69. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25(5):442–53.PubMedGoogle Scholar
  70. Leppert W. The role of methadone in cancer pain treatment – a review. Int J Clin Pract. 2009;63(7):1095–109.PubMedGoogle Scholar
  71. Lickiss JN. Approaching cancer pain relief. Eur J Pain. 2001;5(Suppl A):5–14.PubMedGoogle Scholar
  72. Løhre ET, Klepstad P, Bennett MI, Brunelli C, Caraceni A, Fainsinger RL, Knudsen AK, Mercadante S, Sjøgren P, Kaasa S. From “breakthrough” to “episodic” cancer pain? A European Association for palliative care research network expert Delphi survey toward a common terminology and classification of transient cancer pain exacerbations. J Pain Symptom Manag. 2016;51(6):1013–9.Google Scholar
  73. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;(1).Google Scholar
  74. Lynn TRD, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, Staats PS, Wallace M. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14:E283–312.Google Scholar
  75. Marie N, Luckett T, Davidson PM, Lovell M, Lal S. Optimal patient education for cancer pain: a systematic review and theory-based meta-analysis. Support Care Cancer. 2013;21(12):3529–37.PubMedGoogle Scholar
  76. McConnell T, Scott D, Porter S. Music therapy for end-of-life care: an updated systematic review. Palliat Med. 2016;30:877–83.PubMedGoogle Scholar
  77. McLean S, Twomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manag. 2015;50(2):248–59. e241Google Scholar
  78. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;(8).Google Scholar
  79. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD008025.Google Scholar
  80. McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5:CD012499.PubMedGoogle Scholar
  81. MD Anderson Cancer Center and Cancer Clinical Trials. Methadone, morphine, or oxycodone in treating pain in patients with cancer. From https://clinicaltrials.gov/ct2/show/NCT00726830?term=paracetamol%2C+pain%2C+cancer&rank=18
  82. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, Bogousslavsky J, Baron R. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106(1):151–8.PubMedGoogle Scholar
  83. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–9.PubMedGoogle Scholar
  84. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25(5):504–15.PubMedGoogle Scholar
  85. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manag. 2000;20(4):246–52.Google Scholar
  86. Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, Giarratano A, Casuccio A. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29(6):661–6.PubMedGoogle Scholar
  87. Mercadante S, Klepstad P, Kurita GP, Sjogren P, Giarratano A, European Palliative Care Research Centre. Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015;96(3):577–83.PubMedGoogle Scholar
  88. Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;5:CD003188.Google Scholar
  89. Miller JL, Hagemann TM. Use of pure opioid antagonists for management of opioid-induced pruritus. Am J Health Syst Pharm. 2011;68(15):1419–25.PubMedGoogle Scholar
  90. Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer. 2008;98(12):1934–43.PubMedPubMedCentralGoogle Scholar
  91. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3).Google Scholar
  92. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015a;(7).Google Scholar
  93. Moore RA, Wiffen PJ, Derry S, Lunn MPT. Zonisamide for neuropathic pain in adults. Cochrane Database Syst Rev. 2015b;(1).Google Scholar
  94. National Clinical Effectiveness Committee. Pharmacological management of cancer pain in adults. 2015.Google Scholar
  95. National Clinical Effectiveness Committee. Pharmacological management of cancer pain in adults. 2016.Google Scholar
  96. National Comprehensive Cancer Network. Adult cancer pain. 2016.Google Scholar
  97. NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings. 2013.Google Scholar
  98. NCE Committee. Pharmacological management of cancer pain in adults. 2016.Google Scholar
  99. Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev. 2017;2:CD003971.PubMedGoogle Scholar
  100. O’Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.PubMedGoogle Scholar
  101. Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015;16(10):935–46.PubMedGoogle Scholar
  102. Paley CA, Johnson MI, Tashani OA, Bagnall A-M. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015;10:CD007753.Google Scholar
  103. Pasternak GW. Opioids and their receptors: are we there yet? Neuropharmacology. 2014;76, Part B:198–203.Google Scholar
  104. Paulsen O, Aass N, Kaasa S, Dale O. Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manag. 2013;46(1):96–105.Google Scholar
  105. Paulsen O, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, Kaasa S. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32(29):3221–8.PubMedGoogle Scholar
  106. Peixoto RDA, Hawley P. Intravenous lidocaine for cancer pain without electrocardiographic monitoring: a retrospective review. J Palliat Med. 2014;18(4):373–7.PubMedGoogle Scholar
  107. Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015;6:CD009389.Google Scholar
  108. Porta-Sales J, Garzon-Rodriguez C, Llorens-Torrome S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for palliative care guidelines project. Palliat Med. 2017;31(1):5–25.PubMedGoogle Scholar
  109. Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol. 2014;32(16):1662–70.PubMedGoogle Scholar
  110. Prommer EE. Ketamine for pain: an update of uses in palliative care. J Palliat Med. 2012;15(4):474–83.PubMedGoogle Scholar
  111. Pruskowski J, Arnold RM. A comparison of pregabalin and gabapentin in palliative care #289. J Palliat Med. 2015;18(4):386–7.PubMedGoogle Scholar
  112. Puchalski C, Ferrell B, Virani R, Otis-Green S, Baird P, Bull J, Chochinov H, Handzo G, Nelson-Becker H, Prince-Paul M, Pugliese K, Sulmasy D. Improving the quality of spiritual care as a dimension of palliative care: the report of the consensus conference. J Palliat Med. 2009;12(10):885–904.PubMedGoogle Scholar
  113. Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, Heitzer E, Fainsinger R, Bennett MI, Collaborative O b o t EPCR. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative–Computerised Symptom Assessment study. Palliat Med. 2013;27(8):714–21.PubMedGoogle Scholar
  114. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol. 2010;35(1):2–6.PubMedGoogle Scholar
  115. Royal Australian College of General Practitioners. Pharmaceutical Society of Australia. Australian Medicines Handbook. 2016.Google Scholar
  116. Rueda J-R, Solà I, Pascual A, Subirana Casacuberta M. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst Rev. 2011;9:CD004282.Google Scholar
  117. Salas S, Frasca M, Planchet-Barraud B, Burucoa B, Pascal M, Lapiana JM, Hermet R, Castany C, Ravallec F, Loundou A, Auquier P, Duffaud F, Baumstarck K. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med. 2012;15(3):287–93.PubMedGoogle Scholar
  118. Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer. 2017;25(2):661–75.PubMedGoogle Scholar
  119. Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database Syst Rev. 2015;3:CD009596.Google Scholar
  120. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer-related pain. Cochrane Database Syst Rev. 2017;8:CD003870.PubMedGoogle Scholar
  121. Schug SA, Palmer G, Sco DA, Halliwell R, Trinca J. APM:SE working group of the Australian and New Zealand college of Anaesthetists and Faculty of Pain Medicine. Melbourne: ANZCA and FPM; 2015.Google Scholar
  122. Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer. Scottish Intercollegiate Guidelines Network: Edinburgh; 2008.Google Scholar
  123. Scottish Partnership for Palliative Care. Scottish palliative care guidelines. 2013, 2016. Retrieved 22 Jan 2017, from http://www.palliativecareguidelines.scot.nhs.uk/
  124. Seah DS, Herschtal A, Tran H, Thakerar A, Fullerton S. Subcutaneous lidocaine infusion for pain in patients with cancer. J Palliat Med. 2016; 20(6):667–71.PubMedGoogle Scholar
  125. Shaiova L, Berger A, Blinderman CD, Bruera E, Davis MP, Derby S, Inturrisi C, Kalman J, Mehta D, Pappagallo M, Perlov E. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008;6(2):165–76.PubMedGoogle Scholar
  126. Sharma S, Rajagopal MR, Palat G, Singh C, Haji AG, Jain D. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manag. 2009;37(1):85–93.Google Scholar
  127. Sheinfeld Gorin S, Krebs P, Badr H, Janke EA, Jim HSL, Spring B, Mohr DC, Berendsen MA, Jacobsen PB. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol. 2012;30(5):539–47.PubMedGoogle Scholar
  128. Shepherd TM, Hoch MJ, Cohen BA, Bruno MT, Fieremans E, Rosen G, Pacione D, Mogilner AY. Palliative CT-guided Cordotomy for medically intractable pain in patients with cancer. AJNR Am J Neuroradiol. 2017;38(2):387–90.PubMedGoogle Scholar
  129. Shin E-S, Seo K-H, Lee S-H, Jang J-E, Jung Y-M, Kim M-J, Yeon J-Y. Massage with or without aromatherapy for symptom relief in people with cancer. Cochrane Database Syst Rev. 2016;6:CD009873.Google Scholar
  130. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.Google Scholar
  131. Sperlinga R, Campagna S, Berruti A, Laciura P, Ginosa I, Paoletti S, Giuliano PL, Tucci M, Rosato R, Scagliotti GV, Saini A. Alberta breakthrough pain assessment tool: a validation multicentre study in cancer patients with breakthrough pain. Eur J Pain. 2015;19(7):881–8.PubMedGoogle Scholar
  132. Stannard C, Gaskell H, Derry S, Aldington D, Cole P, Cooper TE, Knaggs R, Wiffen PJ, Moore RA. Hydromorphone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016;5:CD011604.Google Scholar
  133. Straube C, Derry S, Jackson KC, Wiffen PJ, Bell RF, Strassels S, Straube S. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database Syst Rev. 2014;9:CD006601.Google Scholar
  134. Syrmis W, Good P, Wootton J, Spurling G. Opioid conversion ratios used in palliative care: is there an Australian consensus? Intern Med J. 2014;44(5):483–9.PubMedGoogle Scholar
  135. Tassinari D, Drudi F, Rosati M, Tombesi P, Sartori S, Maltoni M. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med. 2011;25(5):410–23.PubMedGoogle Scholar
  136. Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med. 2006;29(1):17–27.PubMedGoogle Scholar
  137. The International Association for the Study of Pain and Taxonomy Working Group. Pain terms. Classification of chronic pain, Second Edition (Revised). Washington, DC; 2011. https://www.iasp-pain.org/Taxonomy?navItemNumber=576
  138. Thomas J, Kronenberg R, Cox MC, Naco GC, Wallace M, Gunten CF v. Intravenous lidocaine relieves severe pain: results of an inpatient hospice chart review. J Palliat Med. 2004;7(5):660–7.PubMedGoogle Scholar
  139. Twycross R; Wilcock A; Howard P; Palliative care formulary 5th Edition. 2016.Google Scholar
  140. Tyson SF, Kent RM. The effect of upper limb orthotics after stroke: a systematic review. NeuroRehabilitation. 2011;28(1):29–36.PubMedGoogle Scholar
  141. University Health Network Toronto. Acetaminophen for cancer pain trial. From https://clinicaltrials.gov/ct2/show/NCT00152854?term=paracetamol%2C+pain%2C+cancer&rank=1
  142. University of Edinburgh Trial. Paracetamol versus placebo in conjunction with strong opioids for cancer pain (PaSO) Trial. From https://clinicaltrials.gov/ct2/show/NCT02706769?term=paracetamol%2C+pain%2C+cancer&rank=6
  143. University of Edinburgh Trial. Two step versus the standard three step approach of the WHO analgesic ladder for cancer pain relief. (TVT) Trial.Google Scholar
  144. University of Florida Trial. Precision medicine guided treatment for cancer pain Trial.Google Scholar
  145. Upadhyay SP, Mallick PN. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates. Am J Hosp Palliat Care. 2012;29(5):388–98.PubMedGoogle Scholar
  146. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51(6):1070–90. e1079Google Scholar
  147. Vellucci R, Fanelli G, Pannuti R, Peruselli C, Adamo S, Alongi G, Amato F, Consoletti L, Lamarca L, Liguori S, Lo Presti C, Maione A, Mameli S, Marinangeli F, Marulli S, Minotti V, Miotti D, Montanari L, Moruzzi G, Palermo S, Parolini M, Poli P, Tirelli W, Valle A, Romualdi P. What to do, and what not to do, when diagnosing and treating breakthrough cancer pain (BTcP): expert opinion. Drugs. 2016;76(3):315–30.PubMedPubMedCentralGoogle Scholar
  148. Ventafridda V, Caraceni A, Gamba A. Field-testing of the WHO guidelines for cancer pain relief-summary report of demonstration projects. Adv Pain Res Ther. 1990;16:451–64.Google Scholar
  149. Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manag. 2014;48(4):619–31.Google Scholar
  150. Wen W, Lynch SY, Munera C, Swanton R, Ripa SR, Maibach H. Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. Expert Opin Drug Saf. 2013;12(3):309–19.PubMedGoogle Scholar
  151. Wiffen PJ, Derry S, Lunn MPT, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013a;(8).Google Scholar
  152. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, Lunn MPT, Hamunen K, Haanpaa M, Kalso EA. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013b;(11).Google Scholar
  153. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014a;(4).Google Scholar
  154. Wiffen PJ, Derry S, Moore RA, Lunn MPT. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev. 2014b;(7).Google Scholar
  155. Wiffen PJ, Derry S, Moore RA, Stannard C, Aldington D, Cole P, Knaggs R. Buprenorphine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015a;9:CD011603.Google Scholar
  156. Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015b;9:CD011460.Google Scholar
  157. Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev. 2016a;12:CD012227.PubMedGoogle Scholar
  158. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2016b;4:CD003868.PubMedGoogle Scholar
  159. Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017a;5:CD012508.PubMedGoogle Scholar
  160. Wiffen PJ, Derry S, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017b;7:CD012637.PubMedGoogle Scholar
  161. Wong RKS, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;2:CD002068.Google Scholar
  162. Wong MHF, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474.Google Scholar
  163. World Health Organisation. Traitement de la doleur cancereuse. Geneva: World Health Organisation; 1987.Google Scholar
  164. World Health Organisation. Cancer pain relief. Geneva: World Health Organisation; 1996.Google Scholar
  165. World Health Organisation. Definition of palliative care. 2016. From http://www.who.int/cancer/palliative/definition/en/
  166. Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med. 2011;25(5):516–24.PubMedGoogle Scholar
  167. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2015;8:CD004311.Google Scholar
  168. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2013;(3).Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.HammondCare Palliative and Supportive Care ServiceGreenwich HospitalSydneyAustralia
  2. 2.Northern Clinical School and Kolling InstituteThe University of SydneySydneyAustralia

Personalised recommendations